Ruby CY Lin, PhD
Ruby joined the Iredell lab at the end of 2017 after a short stint in industry. She is the project manager for Iredell lab and the scientific lead for an investigator-led clinical trial involving treatment of severe Staphylococcal infections using bacteriophage therapy. Her research focus has been microRNA driven dysfunctions in eukaryotic disease model systems including mouse/rat models and humans. She was a named NHMRC Peter Doherty fellow, 2005-8 and UNSW Global postdoctoral fellow, 2009-14. She has acquired >A$5.1m in competitive funding. In her spare time she volunteers as the primary ethics coordinator at her kids’ school and does pro bono work as a career coach.
Tags
- Part 3: Building a sustainable ecosystem for phage therapy This week, Ruby CY Lin of Phage Australia dives further into commercialization pathways and opportunities for Phage Australia, and the phage industry as a whole.
- Part 2: Building a sustainable ecosystem for phage therapy This week, Ruby CY Lin of Phage Australia dives further into commercialization pathways and opportunities for Phage Australia, and the phage industry as a whole.
In Part Two of this three-part series, she explores possible phage therapy…
- Building a sustainable ecosystem for phage therapy This week, Ruby CY Lin of Phage Australia dives deep into commercialization pathways and opportunities for Phage Australia, and the phage industry as a whole.
In Part One of this three-part series, she explains the importance of phage…
- State of the regulatory affair: Regulation of phage therapy in Australia This week, phage researchers and clinicians from the Westmead Institute and Westmead Hospital brief us on how phage therapy is regulated in Australia, through the lens of their experience treating 14 patients with IV phage therapy.
